Abstract: Provided are a display panel and a display apparatus. The display panel comprises: a first substrate and a second substrate that are arranged opposite each other, wherein a display area and a frame area surrounding the display area are provided between the second substrate and the first substrate; a color resistance structure that is located in the frame area on the side of the second substrate facing the first substrate and surrounds the display area, wherein the color resistance structure comprises a first black matrix and a first color resistance portion arranged in a stacked manner; and a plurality of support bars that surround the display area, wherein each of the support bars fills a space between the color resistance structure and the first substrate.

Abstract: The present invention provides a device for testing an allergen antibody in a liquid sample, and the device includes a testing area and a water absorption area, where the testing area is used to contact with liquid, and the water absorption area is located downstream of the testing area and used to absorb the liquid from the testing area; a plurality of first receptors are immobilized onto the testing area, and each of the first receptors is capable to specifically bind to a plurality of different allergen antibodies in the liquid sample. Such a device can be used to once test the presence or absence or level of a plurality of allergen antibodies in the liquid sample, thereby achieving an efficient and convenient testing effect.

Abstract: The present invention provides a device a device for testing an analyte in a liquid sample, comprising a testing area and a water absorption area, wherein the testing area is used to contact with a liquid, and the water absorption area is located downstream of the testing area and used to absorb the liquid from the testing area; one or more first receptors are immobilized onto the testing area; and the first receptor is capable to specifically bind to one analyte or a plurality of different analytes in the liquid sample.

Abstract: A PCIe switch working mode updating method and apparatus, an electronic device, and a computer-readable storage medium, which are applied to a controller. The PCIe switch working mode updating method includes: determining a required switch firmware version of a system according to system configuration information; determining the current switch firmware version according to the current port definition state of a PCIe switch; determining, according to the required switch firmware version and the current switch firmware version, whether a switch port reallocation operation needs to be executed; and under the condition that the switch port reallocation operation needs to be executed, sending, to the PCIe switch, a data file corresponding to the required switch firmware version, so that the PCIe switch updates a working mode according to the data file.

Abstract: An open compute project (OCP) adapter card and a computer device are disclosed. The adapter card includes an OCP connector, a controller, a selector, and a motherboard connector. The OCP connector is configured to connect to an OCP network interface card (NIC). The controller is configured for bandwidth allocation, in-situ control and power-on/off control of the OCP NIC. The selector gates a single-homed host or a dual-homed host based on working mode configuration information stored in the controller. The motherboard connector is configured to connect to a motherboard device.

Abstract: A PCIe switch working mode updating method and apparatus, an electronic device, and a computer-readable storage medium, which are applied to a controller. The PCIe switch working mode updating method includes: determining a required switch firmware version of a system according to system configuration information; determining the current switch firmware version according to the current port definition state of a PCIe switch; determining, according to the required switch firmware version and the current switch firmware version, whether a switch port reallocation operation needs to be executed; and under the condition that the switch port reallocation operation needs to be executed, sending, to the PCIe switch, a data file corresponding to the required switch firmware version, so that the PCIe switch updates a working mode according to the data file. By means of the method, a refreshing mode is simple, an online refreshing operation may be realized, and the flexibility is high.

Abstract: Provided are a display panel and a display apparatus. The display panel comprises: a first substrate and a second substrate that are arranged opposite each other, wherein a display area and a frame area surrounding the display area are provided between the second substrate and the first substrate; a color resistance structure that is located in the frame area on the side of the second substrate facing the first substrate and surrounds the display area, wherein the color resistance structure comprises a first black matrix and a first color resistance portion arranged in a stacked manner; and a plurality of support bars that surround the display area, wherein each of the support bars fills a space between the color resistance structure and the first substrate.

Abstract: An open compute project (OCP) adapter card and a computer device are disclosed. The adapter card includes an OCP connector, a controller, a selector, and a motherboard connector. The OCP connector is configured to connect to an OCP network interface card (NIC). The controller is configured for bandwidth allocation, in-situ control and power-on/off control of the OCP NIC. The selector gates a single-homed host or a dual-homed host based on working mode configuration information stored in the controller. The motherboard connector is configured to connect to a motherboard device.

Abstract: A vibration device, including a housing having accommodating space, a vibrator, a stator and an elastic member, the elastic member is configured to suspend the vibrator in the accommodating space; the vibrator, the stator and the elastic member are accommodated in the housing, the elastic member includes two elastic plate components disposed at two opposite sides of the vibrator, each elastic plate component includes at least two V-shaped elastic plates parallelly arranged perpendicular to vibrating direction, each elastic plate component includes a first fixing portion fixedly connected with the housing, a second fixing portion fixedly connected with the vibrator, and a V-shaped elastic arm connecting the first fixing portion with the second fixing portion, the first and second fixing portions are opposite to and spaced from each other to form an opening end, and the opening ends of two V-shaped elastic plates faces away from each other.

Abstract: The invention discloses a lighted nock device, including a nock body, an LED, a battery, a conductive mounting base, a conductive shift block and an on-off component arranged between the conductive shift block and the conductive mounting base to control connection and disconnection of the conductive shift block and the conductive mounting base. Connection and disconnection of the battery and the LED can be achieved quickly, so that the LED can be turned on or off quickly, with convenient operation and recycling use.

Abstract: A vibration device, including a housing having accommodating space, a vibrator, a stator and an elastic member, the elastic member is configured to suspend the vibrator in the accommodating space; the vibrator, the stator and the elastic member are accommodated in the housing, the elastic member includes two elastic plate components disposed at two opposite sides of the vibrator, each elastic plate component includes at least two V-shaped elastic plates parallelly arranged perpendicular to vibrating direction, each elastic plate component includes a first fixing portion fixedly connected with the housing, a second fixing portion fixedly connected with the vibrator, and a V-shaped elastic arm connecting the first fixing portion with the second fixing portion, the first and second fixing portions are opposite to and spaced from each other to form an opening end, and the opening ends of two V-shaped elastic plates faces away from each other.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.

Abstract: A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in the matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition.

Abstract: A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition.

Abstract: The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.

Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.

Abstract: The present invention relates to a composition containing Rotigotine and the use thereof in the manufacture of a Rotigotine-containing transdermal patch, wherein said composition is based on a matrix mixture system formed from a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive, and polyvinylpyrrolidone which are present in a particular weight ratio, wherein (1) the acrylic pressure-sensitive adhesive is present in an amount of about 1-25% by weight in the matrix mixture system, (2) the silicone pressure-sensitive adhesive is present in an amount of about 65-98% by weight in the matrix mixture system, and (3) the polyvinylpyrrolidone is present in an amount of about 1-10% by weight in the matrix mixture system, and comprises 1-40% of Rotigotine on the basis of the total weight of the composition. The present invention further relates to an improved transdermal patch containing Rotigotine comprising said composition.

Abstract: This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart.